Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

• DOI: 10.6004/jnccn.2023.0045
• Publication Date: 2023-09-06T19:34:06Z
• Authors: David S. Ettinger; Douglas E. Wood; James Stevenson; Dara L. Aisner; Wallace Akerley; Jessica R. Bauman; Ankit Bharat; Debora S. Bruno; Joe Y. Chang; Lucian R. Chirieac; Malcolm DeCamp; Thomas J. Dilling; Jonathan Dowell; Gregory A. Durm; Scott Gettinger; Travis E. Grotz; Matthew A. Gubens; Aparna Hegde; Rudy P. Lackner; Michael Lanuti; Jules Lin; Billy W. Loo; Christine M. Lovly; Fabien Maldonado; Erminia Massarelli; Daniel Morgensztern; Trey C. Mullikin; Thomas Ng; Gregory A. Otterson; Sandip P. Patel; Tejas Patil; Patricio M. Polanco; Gregory J. Riely; Jonathan Riess; Theresa A. Shapiro; Aditi P. Singh; Alda Tam; Tawee Tanvetyanon; Jane Yanagawa; Stephen C. Yang; Edwin Yau; Kristina M. Gregory; Miranda Hughes
• Keywords: Mesothelioma; Mesothelioma, Malignant; Humans; Peritoneum; Medical Oncology; 3. Good health

Mesothelioma is a rare cancer originating in mesothelial surfaces of the peritoneum, pleura, and other sites. These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on peritoneal mesothelioma (PeM). The NCCN Guidelines for PeM provide recommendations for workup, diagnosis, and treatment of primary as well as previously treated PeM. The diagnosis of PeM may be delayed because PeM mimics other diseases and conditions and because the disease is so rare. The pathology section was recently updated to include new information about markers used to identify mesothelioma, which is difficult to diagnose. The term “malignant” is no longer used to classify mesotheliomas, because all mesotheliomas are now defined as malignant.